SCHEMBL2652672

SCHEMBL2652672

FC(F)Oc1ccccc1-c1ncc[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 2/20 0.50
CSNK1A1 P48729 1/20 0.45
TYRO3 Q06418 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
NISCH Q9Y2I1 2/20 0.44
MTOR P42345 1/20 0.44
ADK P55263 1/20 0.44
DRD1 P21728 1/20 0.42
IDO1 P14902 1/20 0.41
SCN9A Q15858 1/20 0.39
CASP6 P55212 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KCNN4 O15554 1/20 0.36
EGFR P00533 1/20 0.36
MC4R P32245 1/20 0.36
KDM4E B2RXH2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29360270 0.78 ADRA1A (0.54) ADRA1ACSNK1A1TYRO3DYRK1BNISCH
SCHEMBL3403152 0.78 ADRA1A (0.54) ADRA1ACSNK1A1TYRO3DYRK1BNISCH
SCHEMBL9287236 0.76 NISCH (0.64) ADRA1ACSNK1A1TYRO3DYRK1BNISCH
SCHEMBL3403159 0.75 ADRA1A (0.58) ADRA1ACSNK1A1TYRO3DYRK1BNISCH
SCHEMBL14886257 0.74 NISCH (0.61) ADRA1ACSNK1A1TYRO3DYRK1BNISCH
SCHEMBL6001642 0.74 ADRA1A (0.50) ADRA1ACSNK1A1TYRO3DYRK1BNISCH
SCHEMBL8536689 0.74 PDE5A (0.59) ADRA1ACSNK1A1TYRO3DYRK1BNISCH
SCHEMBL2652669 0.73 DRD1 (0.41) DRD1ALDH1A1KMT2AKCNN4EGFR
SCHEMBL8538412 0.73 PDE5A (0.57) ADRA1ACSNK1A1TYRO3DYRK1BNISCH
SCHEMBL8541523 0.72 ADRA1A (0.54) ADRA1ACSNK1A1TYRO3DYRK1BNISCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1635813-A4 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA MERCK & CO INC (US) 2009-07-01 EP disclosed
EP-1534074-A4 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO INC (US) 2008-01-09 EP disclosed
EP-1799241-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY Merck & Co., Inc. (US) 2007-06-27 EP disclosed
WO-2006036770-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO., INC. (US) 2006-04-06 WO disclosed
EP-1635832-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES Merck & Co., Inc. (US) 2006-03-22 EP disclosed
EP-1635813-A2 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA Merck & Co. Inc. (US) 2006-03-22 EP disclosed
EP-1635773-A2 COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION Merck & Co., Inc. (a New Jersey corp.) (US) 2006-03-22 EP disclosed
EP-1534074-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY Merck & Co., Inc. (US) 2005-06-01 EP disclosed
WO-2005000217-A2 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA MERCK & CO., INC. (US) 2005-01-06 WO disclosed
WO-2004110375-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES MERCK & CO., INC. (US) 2004-12-23 WO disclosed
WO-2004110368-A2 COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION MERCK & CO., INC. (US) 2004-12-23 WO disclosed
WO-2004009015-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO., INC. (US) 2004-01-29 WO disclosed